This event has already occurred.
John M. Vierling, MD
Risks of Pegylated Interferon Therapies for HCV Infections in Patients with Cirrhosis
Professor, Medicine and Surgery; Chief of Hepatology; Director, Baylor Liver Health; Director, Advanced Liver Therapies; Baylor College of Medicine, St. Luke's Episcopal Hospital, Houston, TX
2 Riverside Circle, Roanoke, VA 24016
More than three million people in the United States are believed to have chronic hepatitis C virus infection. In this seminar, Dr. Vierling will discuss up-to-date data on the efficacy of non-interferon antiviral therapies for hepatitis C infection.